Paper Details

  1. Home
  2. Paper Details

The emerging CDK4/6 inhibitor for breast cancer treatment.

Author: SattiSiem A, SheikhM Saeed

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

CDK4/6 inhibitors have emerged as important cancer therapeutics. Palbociclib, ribociclib, abemaciclib, and dalpiciclib have been approved for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer. These drugs have shown promising results in prolonging progression-free survival.
Paper Details　
Original Abstract of the Article :
The cyclin-dependent kinase (CDK) inhibitors have emerged as important cancer therapeutics. To date, three CDK4/6 inhibitors in combination with endocrine therapy have been approved by the U.S. Food and Drug Administration for the treatment of hormone receptor-positive, HER2-negative advanced breast...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/35251463

データ提供：米国国立医学図書館（NLM）

Targeting Cancer with Precision: CDK4/6 Inhibitors in Breast Cancer Treatment

Breast cancer, a prevalent and complex disease, continues to be a major area of research and development. This study focuses on the emerging role of CDK4/6 inhibitors in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer. CDK4/6 inhibitors have proven effective in combination with endocrine therapy, showing promise in extending progression-free survival. The study provides an overview of the clinical use, effectiveness, and side effects of various CDK4/6 inhibitors, including palbociclib, ribociclib, abemaciclib, and the newest contender, dalpiciclib.

Promising Results for Advanced Breast Cancer

Clinical trials have shown that CDK4/6 inhibitors, when combined with endocrine therapy, can significantly prolong progression-free survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer. This progress offers hope for patients seeking effective treatment options for this challenging disease. The study highlights the importance of ongoing research and development of targeted therapies tailored to specific breast cancer subtypes.

Empowering Breast Cancer Patients

While the study focuses on the potential of CDK4/6 inhibitors, it's important to remember that breast cancer treatment is a multifaceted process. Staying informed about your treatment options, seeking second opinions, and actively participating in your care are crucial steps in navigating this journey. Remember, you are not alone, and resources are available to provide support and guidance.

Dr. Camel's Conclusion

This research serves as a testament to the ongoing advancements in cancer treatment. The emergence of CDK4/6 inhibitors as effective therapeutic agents in breast cancer represents a significant leap forward in precision medicine. The study's findings highlight the importance of personalized treatment approaches and the continuous pursuit of novel therapies to combat this complex disease.
Date :
  1. Date Completed n.d.
  2. Date Revised 2022-08-13
Further Info :

Pubmed ID

35251463

DOI: Digital Object Identifier

NIHMS1780609

Related Literature

Article Analysis
・Side Effects of palbociclib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.